CERo Therapeutics Holdings Receives FDA Clearance For Phase 1 Trials Of Lead Compound CER-1236 In Acute Myelogenous Leukemia (AML)
CERo Therapeutics Holdings Receives FDA Clearance For Phase 1 Trials Of Lead Compound CER-1236 In Acute Myelogenous Leukemia (AML)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.